Keywords
lipid profile, referent value, blood lipids, SCORE scale, cardio-vascular risks, hypolipidemic therapy.
How to Cite
Zuiev, K., & Kohut, D. (2013). Does lipid profile always answer the questions of doctors and patients?. The Practitioner, (2), 61-67. Retrieved from https://plr.com.ua/index.php/journal/article/view/464
Abstract
The article explains the main topics of Guidelines for the management of dyslipidemias (2012) of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) in the estimation of cardio-vascular risks with SCORE system. In the paper, it is stated that modern goal of lipid-lowering therapy in patients with very high level of cardio-vascular risks. The authors ascribe some problems of implementation statements of these Guidelines in Ukraine. Particular attention is paid to the problem of discrepancy of lipid-lowering goals for patients with high and very high level of cardio-vascular risks in blank forms of lipid profile in Ukraine and abroad. In the article, it is elucidated that discrepancies of lipid-lowering goals in blank forms of lipid profile are creating conditions for inadequate lipid-lowering treatment both from the doctor and from the patient.
References
1. Perk J., De Backer G., Gohlke H. et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint
task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by
representatives of nine societies and by invited experts). // Eur Heart J. - 2012. - 33(13). - P. 1635-1701.
2. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the
management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the
European Atherosclerosis Society (EAS). // Eur Heart J. - 2011. - 32(14). - P. 1769-1818.
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). // Lancet. 1994. - 344 (8934). - P. 1383-1389.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk
individuals: a randomised placebo-controlled trial. // Lancet. - 2002. - 360. - P. 8-22.
5. Gaist D., Rodríguez L.A., Huerta C. et al. Lipid-lowering drugs and the risk of myopathy: a population-based follow-up study. // Epidemiology. -
2001. - 12. - P. 565-569.
6. Graham D.J., Staffa J.A., Shatin D. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. // JAMA. - 2004.
- 292. - P. 2585-2590.
7. Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment
Panel III guidelines. // Circulation. - 2004. - 13. - 110(2). - P. 227-239.
8. Materials of IDF 2012.
9. http://internist.ru/sessions/video/2012-10-01-2/2012-10-01-2_1477.html
10. Hansson L., Zanchetti A., Carruthers S.G. et al. the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. // Lancet. - 1998. - 351. - P. 1755-1762.
11. IMS report 2011 data.
12. WHO Model List of Essential Medicines 17th list (March 2011).
13. Heart Protection Study Collaborative Group C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536
patients in the Heart Protection Study. // Lancet. - 2011. - Vol. 377. - Issue 9764. - P. 469-476.
14. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk
individuals: a randomised placebocontrolled trial. // Lancet. - 2002. - Vol. 360. - Issue 9326. - P. 7-22.
15. Dusing R. Adverse events, compliance and changes in therapy. // Curr Hypertens Rep. - 2001. -3. - P. 488-492.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). // Circulation. - 2002. - 106(25). - P. 3143-3421.
17. Rydén L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on
Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes
(EASD). // Eur Heart J. - 2007. - 28(1). - P. 88-136.
task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by
representatives of nine societies and by invited experts). // Eur Heart J. - 2012. - 33(13). - P. 1635-1701.
2. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the
management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the
European Atherosclerosis Society (EAS). // Eur Heart J. - 2011. - 32(14). - P. 1769-1818.
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). // Lancet. 1994. - 344 (8934). - P. 1383-1389.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk
individuals: a randomised placebo-controlled trial. // Lancet. - 2002. - 360. - P. 8-22.
5. Gaist D., Rodríguez L.A., Huerta C. et al. Lipid-lowering drugs and the risk of myopathy: a population-based follow-up study. // Epidemiology. -
2001. - 12. - P. 565-569.
6. Graham D.J., Staffa J.A., Shatin D. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. // JAMA. - 2004.
- 292. - P. 2585-2590.
7. Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment
Panel III guidelines. // Circulation. - 2004. - 13. - 110(2). - P. 227-239.
8. Materials of IDF 2012.
9. http://internist.ru/sessions/video/2012-10-01-2/2012-10-01-2_1477.html
10. Hansson L., Zanchetti A., Carruthers S.G. et al. the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. // Lancet. - 1998. - 351. - P. 1755-1762.
11. IMS report 2011 data.
12. WHO Model List of Essential Medicines 17th list (March 2011).
13. Heart Protection Study Collaborative Group C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536
patients in the Heart Protection Study. // Lancet. - 2011. - Vol. 377. - Issue 9764. - P. 469-476.
14. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk
individuals: a randomised placebocontrolled trial. // Lancet. - 2002. - Vol. 360. - Issue 9326. - P. 7-22.
15. Dusing R. Adverse events, compliance and changes in therapy. // Curr Hypertens Rep. - 2001. -3. - P. 488-492.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). // Circulation. - 2002. - 106(25). - P. 3143-3421.
17. Rydén L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on
Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes
(EASD). // Eur Heart J. - 2007. - 28(1). - P. 88-136.
Downloads
Download data is not yet available.